- Home
- UTL vs XERS Comparison
UTL vs XERS Comparison
Compare UTL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTL
- XERS
- Stock Information
- Founded
- UTL 1984
- XERS 2005
- Country
- UTL United States
- XERS United States
- Employees
- UTL N/A
- XERS N/A
- Industry
- UTL Power Generation
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- UTL Utilities
- XERS Health Care
- Exchange
- UTL Nasdaq
- XERS Nasdaq
- Market Cap
- UTL 842.0M
- XERS 727.1M
- IPO Year
- UTL N/A
- XERS 2018
- Fundamental
- Price
- UTL $51.93
- XERS $4.74
- Analyst Decision
- UTL Hold
- XERS Strong Buy
- Analyst Count
- UTL 1
- XERS 6
- Target Price
- UTL $55.00
- XERS $6.25
- AVG Volume (30 Days)
- UTL 64.3K
- XERS 2.1M
- Earning Date
- UTL 08-05-2025
- XERS 08-07-2025
- Dividend Yield
- UTL 3.51%
- XERS N/A
- EPS Growth
- UTL N/A
- XERS N/A
- EPS
- UTL 2.93
- XERS N/A
- Revenue
- UTL $486,900,000.00
- XERS $222,551,000.00
- Revenue This Year
- UTL $16.37
- XERS $35.03
- Revenue Next Year
- UTL $5.20
- XERS $18.31
- P/E Ratio
- UTL $17.49
- XERS N/A
- Revenue Growth
- UTL N/A
- XERS 29.88
- 52 Week Low
- UTL $49.70
- XERS $2.03
- 52 Week High
- UTL $63.52
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- UTL 40.09
- XERS 54.53
- Support Level
- UTL $51.35
- XERS $4.40
- Resistance Level
- UTL $53.32
- XERS $4.76
- Average True Range (ATR)
- UTL 1.06
- XERS 0.19
- MACD
- UTL 0.04
- XERS 0.03
- Stochastic Oscillator
- UTL 28.23
- XERS 89.80
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).